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Low density lipoprotein apheresis therapy for steroid-resistant Focal and segmental glomerulosclerosis (FGS) is a
nephrotic syndrome. disease manifesting severe nephrotic syndrome (NS) that
Background. The pathogenic role of hyperlipidemia in long- is sometimes resistant to steroid therapy, resulting instanding nephrotic syndrome (NS) is known to be responsible
the rapid decline of renal function [1]. As one of thefor both the progression of glomerulosclerosis and tubulointer-
pathogenic factors known to play a role in the progres-stitial injury, especially in focal segmental glomerulosclerosis
(FGS). sion of renal glomerular and tubular injury in severe
Methods. Aggressive lipid lowering treatment by low density NS, secondary hyperlipidemia has been implicated with
lipoprotein (LDL) apheresis (LDL-A) using a dextran sulfate analogies to atherosclerosis [2]. For persistent chroniccellulose column to treat patients with steroid-resistant or fre-
NS, various lipid lowering therapies have been applied,quently recurrent severe NS was performed first without fixing
including a lipid restricted diet and 3-hydroxy-3-methyl-the protocol in eight patients with FGS and one with minimal
change nephrotic syndrome (MCNS). The period of NS before glutaryl co-enzyme A (HMG-CoA) reductase inhibitor
LDL-A, number and average intervals of LDL-A until the end [3, 4]. Although these trials have resulted in a consider-
of the therapy, and the prognosis were investigated. Next, a
able benefit not only for the hyperlipidemia but for themulticenter study with a fixed protocol of LDL-A treatment
nephrotic state, a rapid achievement of remission in ste-was designed in combination with steroid therapy for treatment
twice a week for three weeks and weekly for six weeks, and roid-resistant NS has not been obtained. Therefore, a
was performed in 17 patients with FGS. The effects on the more aggressive lipid lowering strategy using low density
state of NS in addition to the change of urinary eicosanoid lipoprotein (LDL) apheresis (LDL-A), which selectively
metabolites and remission rates were evaluated.
removes apolipoprotein B-containing lipoproteins fromResults. In the preliminary study, along with a rapid im-
plasma and achieves lower levels of LDL cholesterol,provement of hyperlipidemia, a high incidence of remission
was achieved by LDL-A performed at relatively short intervals. primarily performed to prevent progression of coronary
In the multicenter study with a fixed protocol, there was a atherosclerosis in patients with primary hyperlipidemia
significant decrease of urinary protein (P , 0.001) and increase [5], was attempted in this drug-resistant NS patient popu-of serum albumin (P , 0.02) as well as a decrease of thrombox-
lation. First, a preliminary study with a random protocolane B2 (TXB2) excretion (P , 0.05) after the treatment. Urinary
was performed, and those data were used to design andexcretion of TXB2 was significantly reduced after LDL-A (P ,
0.05). The rate of entering into complete or incomplete remis- execute a multicenter study with a fixed protocol.
sion was 71% with a relatively short duration of nephrotic-
range proteinuria using the LDL-A therapy in comparison with
steroid therapy alone. METHODS
Conclusion. The rapid improvement of hypercholesterol- Patientsemia with LDL-A treatment may provide a new approach for
a high rate of improvement in the degree of NS in steroid- For the preliminary and retrospective studies, during
resistant NS of FGS and MCNS. the latter months of 1989 we performed a random proto-
col LDL-A therapy that included nine episodes of ste-
roid-resistant NS in eight patients who had been diag-Key words: thromboxane B2, progressive renal disease, tubulointersti-
nosed with FGS or MCNS [6]. For the multicenter studytial injury, focal segmental glomerulosclerosis, minimal change ne-
phrotic syndrome. with a fixed protocol, 17 steroid-resistant NS patients
(14 FGS and 3 MCNS) were entered into the study. 1999 by the International Society of Nephrology
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Fig. 1. Treatment schedule of low density li-
poprotein aphoresis (LDL-A) in combination
with full-dose steroids.
Treatment schedule of low density in six episodes (67%) in five patients (Table 1). The
lipoprotein apheresis remaining three patients were resistant to this therapy,
and one manifested renal failure within six months. TheLow density lipoprotein apheresis was performed us-
number of and intervals between LDL-A treatments ining polysulfone hollow fiber filters (Sulflux; Nikkiso,
the response group were significantly less than those inTokyo, Japan) as the plasma separator and a dextran
the resistant-group. Immunohistological study showed asulfate cellulose column (Liposorber LA-15; Kaneka
reduction in high intensity of mesangial apoprotein BCorp., Osaka, Japan) as the LDL absorber. Plasma (from
staining and intraglomerular macrophage infiltration3000 ml to 4000 ml, or ca. 60 ml/kg wt) was treated for
after LDL-A in five of six patients [6].three hours during each apheresis treatment. The fixed
protocol consisted of LDL-A twice a week for three
Multicenter study with fixed protocolweeks followed by weekly LDL-A for six weeks after at
Significant decreases in serum cholesterol and phos-least one month of full-dose steroid treatment (Fig. 1).
pholipid levels were shown along with a significant reduc-The same dose of steroid therapy was maintained until
tion of proteinuria and an increase in serum albuminthe end of the protocol.
after the treatment (Table 2). There was no significant
Parameters evaluated change in the average CCr and serum Cr (SCr) levels after
LDL-A. Urinary TXB2 excretion as an index of renalIn the preliminary study, the period of NS before
TXA2 production showed a significant decrease afterLDL-A, number and average intervals of LDL-A treat-
ment until the end of the therapy, and the prognosis LDL-A therapy. Remission and incomplete remission
were investigated. For the multicenter study, changes of were observed in eight (47%) and four (24%) patients,
urinary and serum protein, lipid metabolism and renal respectively. The average duration needed for a decrease
function after treatment, the rate of achieving remission of urinary protein to less than 3.5 g/day was 14.7 6 19.6
and the duration of the nephrotic state were also evalu- days [8].
ated. As the true glomerular filtration rate (GFR) is
overestimated by approximately 40% by conventional
DISCUSSIONmeasurement of creatinine clearance (CCr) during active
The effects of LDL-A were relatively rapid and some-NS [7], the evaluation of renal function was performed
times enabled the early reduction of the dosage of corti-by combining with blood urea nitrogen (BUN) levels.
costeroid that was concomitantly used. However, in theIn addition, daily urinary excretion of thromboxane B2
preliminary study, since LDL-A was performed in com-(TXB2) and 6-keto-PGF1a were also measured before
bination with steroid and other immunosuppressive ther-and after the therapy.
apy, it was not clear whether these preferential effects
could be mainly attributed to LDL-A. The multicenter
RESULTS study with a fixed protocol also revealed a high ratio
Preliminary study of remission in combination with steroid therapy. To
compare these results with the patients treated with ste-Retrospective analysis of the results demonstrated a
roids alone, we randomly and retrospectively selectedremarkable amelioration of nephrotic proteinuria with
10 steroid-resistant NS patients (FGS: 9, MCNS:1) frommarked elevation of serum protein levels, and the main-
tenance and sometimes improvement in renal function those showing steroid resistance for at least four weeks
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Table 1. Patient profile and treatment of preliminary study
LDL-A
Before LDL-A
period of NS N of LDL-A Average interval
No. Case Age Sex Disease (months) treatment (days) Prognosis
Response group
1 N.M. 16 F MCNS 4 10 8.8 Remission
2 O.U. 46 M FGS 1.5 4 3.3 Remission
3 H.Y. 22 F FGS 0.5 2 3 Remission
4 Y.M. 26 M FGS 3 7 13.8 Remission
5 Y.M. FGS 1.5 5 3.25 Incomplete
6 U.N. 42 M FGS1MN 1.5 2 3 Remission
Resistant group
7 I.M. 21 F FGS 3 11 12.4 Stationary NS
8 N.S. 56 F FGS 26 12 12.5 Stationary NS
9 O.T. 25 M FGS 10 13 16.4 Stationary NS
Patients were evaluated 2 weeks after the final LDL-A treatment. Definitions are: remission, daily proteinuria , 3.5 g/day and serum albumin . 3.0 g/dl; incomplete
remission, daily proteinuria , 3.5 g/day but serum albumin , 3.0 g/dl; stationary NS, daily proteinuria , 3.5 g/day and serum albumin , 3.0 g/dl.
Table 2. Effects of LDL-A on serum lipids, serum protein, urinary nism for these effects of LDL-A. Among these are: (a)
protein, renal function and urinary TXB2 and 6-keto-PGF1a in 17 improvement of hypercoagulability by reduction of thesteroid-resistant NS patients
coagulation factors V, VIII von Willebrand’s factor
LDL-apheresis (vWF), and prekallikrein [9]; (b) improvements in renal
Before After P hemodynamics by reducing the vasoconstrictive eicosa-
TC mg/dl 3376118 242 645.2 0.006 noids (such as thromboxane A2) and increasing prosta-
TG mg/dl 2256126 205 6151 0.525 glandin I2 [10]; (c) decreasing a proinflammatory statePL mg/dl 324677 241 657 0.006
by absorbing potentially noxious lipids (such as oxidizedHDL-C mg/dl 69.2630.7 64.5 631.7 0.459
TP g/dl 4.660.8 5.0 60.9 0.078 LDL); and (d) suppression of intraglomerular invasion
ALB g/dl 2.760.7 3.1 60.7 0.014 of macrophages that sometimes form foam cells, trapping
UP g/day 6.263.3 2.7 62.7 0.0008
the abnormally increased circulating lipoproteins [6].CCr ml/min 84.3655.5 79.2 630.0 0.622
BUN mg/dl 221.4619.0 17.8 615.2 0.043 Considering the relatively rapid effect of LDL-A on the
TXB2 ng/day 1187.361478.8 570.5 6639.7 0.047 nephrotic proteinuria both in the preliminary and in the
6-keto-PGF1-a
fixed protocol studies, the amelioration of renal vascularng/day 11.1610.6 8.4 66.3 0.286
contraction, possibly by a reduction in TXA2 production,Data are mean 6 sd.
may partly contribute to this rapid response. The signifi-
cant decrease of the urinary excretion of TXB2 in the
fixed protocol study was consistent with this hypothesis.
and who had been treated by full-dose steroid alone until Oxidized LDL induces systemic and local increases of
remission or for nine weeks in comparison to the LDL-A cytokine and chemokine secretion [11]. Macrophages
treated patients. Evaluation of the effect of this therapy activated by oxidized LDL through scavenger receptors
revealed no significant improvement of average levels of may be the major source of these substances, which also
hypercholesterolemia (448 6 106 to 336 6 159 mg/dl), stimulate macrophages in an autocrine manner. Reduc-
hypoproteinemia (4.8 6 0.8 g/dl before therapy to 4.9 6 tion in the stimulation of macrophage by adsorption of
1.1 after therapy) and urinary daily protein (8.7 6 4.0 oxidized LDL-A may provide not only a prolonged effect
to 8.2 6 7.7 g/day) within this therapy period. There was in reducing local foam cell formation, but a rapid de-
also no apparent improvement either of CCr (65.7 6 30.1 crease of the hyperpermeability of the capillary wall that
to 54.1 6 27.9 ml/min) nor of BUN (33.5 6 19.9 to may have contributed to the massive proteinuria seen
30.4 6 20.6 mg/dl) after the therapy. Remission and in these patients.
incomplete remission were observed only in two (20%) As our protocol called for the use of LDL-A after at
and one patient (10%), respectively, with a significantly least one month of full-dose steroid treatment, which
longer average duration of NS (47.8 6 6.9 days) com- was continued after starting LDL-A therapy, another
pared with the LDL-A group (P , 0.01). These results possible effect of the LDL-A was the improvement in
indicated that a rapid improvement of hypercholesterol- response to steroids. Considering the finding that very-
emia by LDL-A in steroid-resistant NS may provide low density lipoprotein (VLDL) induces a dose-depen-
more rapid relief from NS in comparison with steroid dent reduction in the number of specific binding sites
therapy alone. for dexamethadone in cultured smooth muscle cells, hy-
perlipidemia may inhibit steroid responsiveness. It isSeveral candidates can be nominated to be the mecha-
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ian soy diet on hyperlipidemia in nephrotic syndrome. Lancettherefore possible that rapid lowering of LDL may up-
339:1131–1134, 1992
regulate the steroid binding of various cells in NS. On 4. Kasiske BL, Velosa JA, Halstenson CE, La Belle P, Langen-
dorfer A, Keane WF: The effects of lovastatin in hyperlipidemicthe other hand, because LDL-A also has been shown to
patients with nephrotic syndrome. Am J Kidney Dis 15:8–15, 1990induce a remission of NS before using steroid [12], the 5. Thompson GR, Miller JP, Breslow JL: Improved survival of
mechanism of action by LDL-A cannot be explained patients with homozygous familial hypercholesterolaemia treated
by plasma exchange. Br Med J 291:621–1673, 1985solely on the basis of an improvement in steroid respon-
6. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K,siveness. Sasayama S: Does LDL-apheresis in steroid-resistant nephrotic
syndrome affect prognosis? Nephrol Dial Transplant 9:257–264,Since relatively rapid improvement was observed over
1997short intervals between LDL-A procedures, we suggest
7. Carrie BJ, Gobetz HV, Michaels AS: Creatinine: An inadequate
that LDL-A should be performed at least twice a week, filtration marker in glomerular diseases. Am J Med 69:177–182,
1980especially at the initiation of treatment. As the patho-
8. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A,genic influence of long-standing proteinuria on the out- Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara
Y, Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group:come of renal function becomes more apparent [13],
Significantly rapid induction of remission of steroid-resistant ne-therapeutic techniques such as LDL-A that reduce pro-
phrotic syndrome by LDL-apheresis. (manuscript submitted)
teinuria may be of additional benefit to steroid therapy 9. Knisel W, Di Nicuolo A, Pfohl M, Muller H, Risler T,
Eggstein M, Seifried E: Different effects of two methods of low-in patients with resistant nephrotic syndrome secondary
density lipoprotein apheresis on the coagulation and fibrinolyticto FGS. systems. J Intern Med 234:479–487, 1993
10. Kaplan R, Aynedjian HS, Schlondorff D, Bank N: Renal vaso-
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